|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
MaxCyte, Inc.® VLX™ and STX™ Transient Transfection Systems Are Acquired by Paragon Bioservices for Use in Vaccine and Protein Manufacturing
1/29/2013 9:45:31 AM
GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is pleased to announce that Paragon Bioservices has acquired both the MaxCyte VLX® Large Scale Transfection System and the MaxCyte STX® Scalable Transfection System for use in contract manufacturing of recombinant proteins, antibodies, viral vectors, vaccines, and VLPs. The initial application of MaxCyte STX and VLX systems will be in fulfillment of a Department of Defense contract for the process development and manufacturing scale-up of VLP-type vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses in support of the ongoing preclinical evaluation of the efficacy, potency, and safety of these Filovirus vaccine candidates.
|
|
|
|
|
|
|
|
|
|
|